What is Monopar Therapeutics's asset turnover?

Monopar Therapeutics (MNPR) reported asset turnover of 0× in Q1 2026.

What does asset turnover mean?

Trailing-twelve-month revenue divided by average total assets. Measures how many dollars of sales each dollar of assets generates — the efficiency leg of the DuPont decomposition of ROE.

Monopar Therapeutics MNPR Asset turnover

Asset turnover at other companies

Bristol-Myers SquibbBMY

0.5×0.0×

Eli LillyLLY

0.7×+0.1×

Bausch Health CompaniesBHC

0.4×0.0×

Ultragenyx PharmaceuticalRARE

0.5×+0.1×

Prime MedicinePRME

0×0.0×

Wave Life SciencesWVE

0.5×+0.3×

Other financials

Income statement

See full

Revenue-—

Operating income-$5.2M-62.2%

Net income-$3.9M-48.3%

EPS (diluted)-$0.19—

Balance sheet

See full

Cash & equivalents$52.5M+32.3%

Total debt$230.4K+2,692%

Total equity$135.4M+153%

Total assets$138.0M+150%

Cash flow

See full

Operating cash flow-$3.5M+38.7%

Valuation

See full

Market cap$587.04M+192%

Enterprise value$534.72M+232%

Returns & leverage

See full

Return on equity-15.9%-6.6pp

Debt / equity0×0.0×

Current ratio56×—

Where this comes from

Calculated from Monopar Therapeutics’s reported figures.

total revenue/total assets=0×

Based on trailing twelve months.

The official record: Monopar Therapeutics’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Monopar Therapeutics's asset turnover.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Monopar Therapeutics's asset turnover?: Monopar Therapeutics (MNPR) reported asset turnover of 0× in Q1 2026.
What does asset turnover mean?: Trailing-twelve-month revenue divided by average total assets. Measures how many dollars of sales each dollar of assets generates — the efficiency leg of the DuPont decomposition of ROE.